XML 27 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Stock Compensation Plans
9 Months Ended
Jun. 30, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Stock Compensation Plans
STOCK COMPENSATION PLANS

Under the Company’s 2003 Stock Option Plan, the Company was able to grant options for up to 300,000 shares of common stock to employees, officers, directors and directors emeriti.  Under the Company's 2014 Equity Incentive Plan, the Company is able to grant options and awards of restricted stock (with or without performance measures) for up to 352,366 shares of common stock to employees, officers, directors and directors emeriti.  Shares issued may be purchased in the open market or may be issued from authorized and unissued shares.  The exercise price of each option equals the fair market value of the Company’s common stock on the date of grant. Generally, options and restricted stock vest in 20% annual installments on each of the five anniversaries from the date of the grant, and options generally have a maximum contractual term of ten years from the date of grant. At June 30, 2019, there were 75,316 shares of common stock available which may be awarded as options or restricted stock pursuant to future grant under the 2014 Equity Incentive Plan.

At both June 30, 2019 and 2018, there were no unvested restricted stock awards. There were no restricted stock grants awarded during the nine months ended June 30, 2019 or 2018.

Stock option activity for the nine months ended June 30, 2019 and 2018 is summarized as follows:
 
Nine Months Ended
June 30, 2019
 
Nine Months Ended
June 30, 2018
 
 Number of Shares

 
Weighted
Average
Exercise
Price

 
 Number of Shares

 
Weighted
Average
Exercise
Price

Options outstanding, beginning of period
380,820

 
$
16.03

 
380,120

 
$
13.23

Exercised
(37,756
)
 
9.00

 
(34,850
)
 
8.39

Forfeited
(3,900
)
 
18.63

 
(5,150
)
 
13.39

Options outstanding, end of period
339,164

 
$
16.79

 
340,120

 
$
13.73



The aggregate intrinsic value of options exercised during the nine months ended June 30, 2019 and 2018 was $751,000 and $741,000, respectively.

At June 30, 2019, there were 155,750 unvested options with an aggregate grant date fair value of $485,000, all of which the Company assumes will vest. The aggregate intrinsic value of unvested options at June 30, 2019 was $1.09 million.  There were 37,300 options with an aggregate grant date fair value of $88,000 that vested during the nine months ended June 30, 2019.

At June 30, 2018, there were 183,150 unvested options with an aggregate grant date fair value of $454,000. There were 43,900 options with an aggregate grant date fair value of $104,000 that vested during the nine months ended June 30, 2018.
 
 

Additional information regarding options outstanding at June 30, 2019 is as follows:
 
 
Options Outstanding
 
Options Exercisable
Range of
Exercise
Prices ($)
 
Number

 
Weighted
Average
Exercise
Price

 
Weighted
Average
Remaining
Contractual
Life (Years)
 
Number

 
Weighted
Average
Exercise
Price

 
Weighted
Average
Remaining
Contractual
Life (Years)
$ 4.01 - 4.55
 
2,500

 
$
4.33

 
1.2
 
2,500

 
$
4.33

 
1.2
   5.86 - 6.00
 
19,850

 
5.97

 
3.3
 
19,850

 
5.97

 
3.3
   9.00
 
52,775

 
9.00

 
4.3
 
52,775

 
9.00

 
4.3
 10.26 - 10.71
 
113,189

 
10.58

 
5.8
 
79,989

 
10.55

 
5.7
 15.67
 
48,800

 
15.67

 
7.3
 
17,000

 
15.67

 
7.3
 29.69
 
56,100

 
29.69

 
8.3
 
11,300

 
29.69

 
8.3
 31.80
 
45,950

 
31.80

 
9.3
 

 
N/A

 
N/A
 
 
339,164

 
$
16.79

 
6.5
 
183,414

 
$
11.18

 
5.3


The aggregate intrinsic value of options outstanding at June 30, 2019 and 2018 was $4.53 million and $8.03 million, respectively.

As of June 30, 2019, unrecognized compensation cost related to non-vested stock options was $401,000, which is expected to be recognized over a weighted average life of 2.14 years.